Translational Nanomedicine Research Laboratory

Open positions

Highly motivated graduate students and postdocs interested in nano-drug delivery should send their CV to Dr. Anjali Sharma at anjali.sharma@wsu.edu

National Institutes of Health (NIH) – National Eye Institute (NEI-R01) Nanotherapies for Targeted Treatment of Corneal Neovascularization. Aug 1, 2025 – June 30, 2030. (Role PD/PI) $2.6M
National Institutes of Health (NIH) – National Institute of Neurological Disorders and Stroke (NINDS-R01). Targeted Nanotherapies for the Treatment of Brain Disorders. Aug 1, 2025 – May 31, 2030. (Role: PD/PI) $2.6M
Andy Hill Care Fund (Washington Cancer Research Foundation). In Vivo Imaging Capabilities to Enable Investigations Focused on Cancer Mechanisms and Therapeutic Outcomes. July 1, 2023-June 30, 2026. $1.3M (Role: PI)
National Institutes of Health (NIH) – National Cancer Institute (NCI-R21). Targeted Nanotherapies for the Treatment of Prostate Cancer. July 1, 2024 – June 30, 2026. $406,520 (Role: PI)
Murdock Commercialization Initiation Grant. Dec. 1, 2024-Nov 30, 2026. $150,000 (Role: PI)
Washington Research Foundation (WRF). Dendrimer Nanotherapy for Targeted Treatment of Prostate Cancer. July 1,2024-Dec 31, 2025. $100,000 (Role: PI)
Washington State University-Commercialization Gap Fund. $50,000
Washington State University-New Faculty Seed Grant. PSMA-Targeted Dendrimer Nanomedicines for Prostate Cancer. May 16, 2023-Aug 15, 2024. (Role: PI)